ストックスクリーナーアプリを入手
9.4826
1.55%
0.1526
前日終値:
$9.33
開ける：
$9.43
24時間の取引高:
182.21K
Relative Volume:
0.28
時価総額：
$561.50M
収益：
-
当期純損益:
$-106.81M
株価収益率:
-4.3103
EPS:
-2.2
ネットキャッシュフロー:
$-8.40M
1週間 パフォーマンス:
-14.95%
1か月 パフォーマンス:
-20.45%
6か月 パフォーマンス:
-30.59%
1年 パフォーマンス:
+19.18%
1日の値動き範囲:
$9.05
$9.7123
1週間の範囲:
$8.97
$11.19
52週間の値動き範囲:
$6.93
$30.96
Immunome Inc Stock (IMNM) Company Profile
IMNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| IMNM | 9.45 | 561.50M | 0 | -106.81M | -8.40M | -2.20 |
| VRTX | 447.31 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.17 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.86 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 104.13 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-04-30 | 開始されました | JP Morgan | Overweight |
| 2024-04-15 | 開始されました | Guggenheim | Buy |
| 2024-01-29 | 開始されました | Leerink Partners | Outperform |
| 2023-12-19 | 開始されました | Wedbush | Outperform |
| 2021-10-29 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Immunome Inc (IMNM) 最新ニュース
Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Wedbush Has Bullish Outlook for Immunome FY2024 Earnings - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for Immunome - MarketBeat
FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs - Defense World
Immunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline Progress - Defense World
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Immunome (NASDAQ:IMNM) Stock Price Down 7% After Analyst Downgrade - Defense World
T. Rowe Price Investment Management, Inc. Expands Stake in Immun - GuruFocus.com
Piper Sandler maintains overweight on IMNM with $21 target By Investing.com - Investing.com Canada
Piper Sandler maintains overweight on IMNM with $21 target - Investing.com India
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Janus Henderson Group's Strategic Acquisition of Immunome Inc Sh - GuruFocus.com
Immunome (NASDAQ:IMNM) Shares Down 7% Following Analyst Downgrade - MarketBeat
Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00 - MarketBeat
Immunome price target lowered to $21 from $23 at Piper Sandler - TipRanks
Immunome, Inc. Reports Q3 2024 Financial Results - TipRanks
Immunome Inc (IMNM) Q3 2024 Earnings: Revenue Surpasses Estimates at $2.91M, GAAP EPS Misses at -$0.78 - GuruFocus.com
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunome Reports $47.1M Q3 Loss, Advances Cancer Pipeline with Strong Cash Position | IMNM Stock News - StockTitan
(IMNM) Technical Pivots with Risk Controls - Stock Traders Daily
Immunome earnings missed by $0.24, revenue topped estimates - Investing.com Canada
FMR LLC's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com
Immunome (NASDAQ:IMNM) Shares Gap Up – Still a Buy? - Defense World
Stephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight Recommendation - MSN
Analyst Expectations For Immunome's Future - Benzinga
Immunome (NASDAQ:IMNM) Shares Gap UpTime to Buy? - MarketBeat
Immunome (NASDAQ:IMNM) Now Covered by Stephens - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Stake Reduced by Wealth Enhancement Advisory Services LLC - Defense World
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference - The Bakersfield Californian
Vanguard Group Inc's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com
Immunome (NASDAQ:IMNM) Trading Up 8.7%Time to Buy? - MarketBeat
Learn to Evaluate (IMNM) using the Charts - Stock Traders Daily
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Average PT from Brokerages - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World
Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World
Immunome Advances with Strategic Asset Acquisition and Agreement - Yahoo Finance
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 - Business Wire
Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 15.2% in October - MarketBeat
Immunome's (IMNM) Outperform Rating Reiterated at Wedbush - MarketBeat
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium - The Bakersfield Californian
IMNMImmunome, Inc. Latest Stock News & Market Updates - StockTitan
Immunome (IMNM) Price Target Increased by 179.17% to 34.17 - MSN
Cubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Cubist Systematic Strategies LLC Decreases Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily
Financial Metrics Exploration: Understanding Immunome Inc (IMNM) Through Ratios - The Dwinnex
Sei Investments Co. Cuts Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
(IMNM) Investment Analysis and Advice - Stock Traders Daily
Insider Selling: Rosett Max, Immunome Inc [IMNM] Chief Financial Officer divested 14,380 shares - Knox Daily
Immunome Inc (IMNM) 財務データ
収益
当期純利益
現金流量
EPS
Immunome Inc (IMNM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Sale |
16.01 |
14,380 |
230,224 |
47,476 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):